Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Cancer Prev Res (Phila). 2015 Oct 28;9(1):43–52. doi: 10.1158/1940-6207.CAPR-14-0287

Figure 6. Preliminary evaluation of NAA as a circulating biomarker for lung cancer.

Figure 6

NAA blood levels in healthy controls (“Control”) vs. NSCLC patients (“Cancer”) at 55 years of age or younger (** = p<0.01, * = p<0.05). Filled circles indicate nine NSCLC patients diagnosed as stage 1A. Horizontal lines and error bars indicate means and standard errors of NAA blood levels.